RB1 and neoplasm: Our findings suggest that patients with well-sampled tumours fulfilling the WHO criteria for AA (Kleihues and Cavanee, 2000) having genetic abnormalities affecting any of the genes coding for the components of the Rb1 pathway have a poor outcome.